Equities Research Analysts’ updated eps estimates for Friday, September 8th:

Abeona Therapeutics (NASDAQ:ABEO) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $20.00 target price on the stock.

Ameren Corporation (NYSE:AEE) had its equal weight rating reissued by analysts at Morgan Stanley.

American Electric Power (NYSE:AEP) had its equal weight rating reaffirmed by analysts at Morgan Stanley.

The AES Corporation (NYSE:AES) had its equal weight rating reissued by analysts at Morgan Stanley.

Aflac (NYSE:AFL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Aflac shares have outperformed its industry year to date. Efforts to increase agent productivity, emphasis on sale of third-sector products, pull back on sale of first-sector products, and the introduction of new products like cancer insurance are likely to drive long-term growth. Its strong capital position enables it to buy back shares and increase dividend payouts. However, the company remains exposed to a challenging operating environment, primarily in Japan. Charges related to Japan’s branch conversion and foreign exchange volatility are some headwinds faced by the company.”

Ashmore Group (OTC:AJMPF) was upgraded by analysts at BNP Paribas from an underperform rating to a neutral rating.

Abraxas Petroleum Corporation (NASDAQ:AXAS) had its buy rating reaffirmed by analysts at Canaccord Genuity.

Brighthouse Fin (NASDAQ:BHF) was upgraded by analysts at Bank of America Corporation from an underperform rating to a neutral rating. Bank of America Corporation currently has $63.00 price target on the stock.

Bob Evans Farms (NASDAQ:BOBE) had its hold rating reissued by analysts at Oppenheimer Holdings Inc.. They currently have a $72.00 price target on the stock.

CASI Pharmaceuticals (NASDAQ:CASI) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $2.00 price target on the stock.

CASI Pharmaceuticals (NASDAQ:CASI) had its buy rating reiterated by analysts at Maxim Group. The firm currently has a $4.00 price target on the stock. The analysts wrote, “Summary CASI provided both a Pipeline Update and a review of the regulatory status of its in-licensed drugs EVOMELA, MARQIBO and ZEVALIN in China. We see a focused company executing on two fronts. One creates platform value and the other, pipeline value.””

Carnival Corporation (NYSE:CCL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Carnival shares have outpaced the industry in the past year. Given burgeoning demand for cruise travel in 2017, the addition of new ships to its fleet bodes well. Carnival believes that it is well positioned for continued earnings growth, given the current strength in its bookings along with pricing trends for the year. Notably, its brand building efforts together with other marketing activities are driving bookings. Its strategy of growing beyond familiar itineraries and capitalizing on fast growing markets is likely to further drive growth. Meanwhile, estimates have been stable lately ahead of its fiscal thirdd quarter earnings release and the company has positive record of earnings surprises in recent quarters. However, adverse forex translations, higher costs along with macroeconomic issues in key operating regions remain headwinds. A potential increase in fuel costs can also hamper its profitability.”

Comerica (NYSE:CMA) had its buy rating reissued by analysts at FBR & Co. The firm currently has a $79.00 price target on the stock.

CMS Energy Corporation (NYSE:CMS) had its hold rating reissued by analysts at Morgan Stanley. Morgan Stanley currently has a $50.00 target price on the stock, up from their previous target price of $49.00.

Conn’s (NASDAQ:CONN) had its hold rating reiterated by analysts at Oppenheimer Holdings Inc..

ConocoPhillips (NYSE:COP) had its buy rating reissued by analysts at Scotiabank. They currently have a $52.00 target price on the stock.

Delek US Holdings (NYSE:DK) had its hold rating reissued by analysts at Scotiabank. The firm currently has a $26.00 target price on the stock.

Dollarama (TSE:DOL) was upgraded by analysts at Desjardins from a hold rating to a buy rating. The firm currently has C$154.00 target price on the stock, up from their previous target price of C$134.00.

US Ecology (NASDAQ:ECOL) had its buy rating reiterated by analysts at Canaccord Genuity. The firm currently has a $60.00 price target on the stock.

Equifax (NYSE:EFX) had its buy rating reaffirmed by analysts at J P Morgan Chase & Co.

Alphabet (NASDAQ:GOOGL) had its buy rating reissued by analysts at UBS AG.

Hasbro (NASDAQ:HAS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Hasbro‘s earnings have topped the Zacks Consensus Estimate in all the trailing 10 quarters. Revenues too have been surpassing the consensus mark, except for the last quarter. Consistent efforts to establish its global presence via strategic partnerships and rapid growth in emerging markets should continue driving the top- and bottom–line performance. However, Hasbro’s shares underperformed the industry year to date. Even so, this year’s rich content slate, new product launches, various sales boosting initiatives along with a favorable gaming portfolio is likely to drive growth ahead. Going forward, the Franchise and Partner Brands, particularly, are expected to perform consistently in 2017 given global digital content and innovative offerings. Yet, rising competition from alternative modes of entertainment might limit top-line growth, while high costs along with macroeconomic and currency headwinds may dent profits.”

HollyFrontier Corporation (NYSE:HFC) had its buy rating reaffirmed by analysts at Scotiabank. They currently have a $33.00 target price on the stock.

Harley-Davidson (NYSE:HOG) had its buy rating reaffirmed by analysts at BMO Capital Markets. They currently have a $56.00 price target on the stock.

Hercules Capital (NYSE:HTGC) was upgraded by analysts at Compass Point from a neutral rating to a buy rating.

Mastercard (NYSE:MA) had its buy rating reaffirmed by analysts at Oppenheimer Holdings Inc.. The firm currently has a $145.00 target price on the stock.

Micro Focus International plc (LON:MCRO) had its underperform rating reaffirmed by analysts at Credit Suisse Group. They currently have a GBX 1,921 ($24.81) target price on the stock.

Major Drilling Group Int'l (TSE:MDI) was downgraded by analysts at TD Securities from a buy rating to a hold rating. TD Securities currently has C$9.00 target price on the stock, down from their previous target price of C$9.50.

Merck & (NYSE:MRK) had its buy rating reiterated by analysts at BMO Capital Markets. BMO Capital Markets currently has a $72.00 target price on the stock.

MagnaChip Semiconductor Corporation (NYSE:MX) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $15.00 target price on the stock.

NCI Building Systems (NYSE:NCS) had its buy rating reissued by analysts at Barclays PLC. The firm currently has a $16.00 target price on the stock, down from their previous target price of $19.00.

Janney Montgomery Scott began coverage on shares of NexPoint Residential Trust (NYSE:NXRT). Janney Montgomery Scott issued a neutral rating on the stock.

ObsEva SA (NASDAQ:OBSV) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $27.00 price target on the stock.

Phillips 66 (NYSE:PSX) had its hold rating reiterated by analysts at Scotiabank.

Paramount Gold Nevada Corp (NYSE:PZG) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $4.00 target price on the stock.

Stingray Digital Group (TSE:RAY.A) was downgraded by analysts at TD Securities from a buy rating to a hold rating. They currently have C$10.00 price target on the stock, up from their previous price target of C$9.50.

ResMed (NYSE:RMD) had its sell rating reissued by analysts at Needham & Company LLC.

Seattle Genetics (NASDAQ:SGEN) had its hold rating reissued by analysts at Cann. The analysts wrote, “Seattle Genetics announced today that preliminary clinical data for tisotumab vedotin from a Genmab-sponsored phase I/II clinical trial, GEN701, are being featured in an oral presentation at ESMO. Data were reported from an expansion cohort of the study including 34 patients with relapsed, recurrent and/or metastatic cervical cancer. It was reported that 32% of these patients achieved a response and 50% of patients achieved clinical benefit after 12 weeks. Median duration of confirmed responses was 8.3 months.””

Synergy Pharmaceuticals (NASDAQ:SGYP) had its buy rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $11.00 price target on the stock.

Sigma Designs (NASDAQ:SIGM) had its hold rating reiterated by analysts at Needham & Company LLC.

Sierra Metals (NASDAQ:SMTS) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $3.50 price target on the stock.

Symantec Corporation (NASDAQ:SYMC) had its hold rating reiterated by analysts at Robert W. Baird. They currently have a $32.00 price target on the stock.

Atlassian Corporation PLC (NASDAQ:TEAM) had its buy rating reissued by analysts at Oppenheimer Holdings Inc..

TransUnion (NYSE:TRU) had its buy rating reissued by analysts at Deutsche Bank AG.

TESARO (NASDAQ:TSRO) had its buy rating reiterated by analysts at Cann. They currently have a $199.00 price target on the stock. The analysts wrote, “These results are an analysis of the phase I/II TOPACIO study of niraparib plus pembrolizumab in combination with pembrolizumab (Keytruda) in patients with triple negative breast cancer (TNBC) or ovarian cancer. Safety and efficacy were presented from both the dose-finding portion as well as the dose-expansion portion of the study. We believe these data released today support a path forward for Tesaro in the TNBC setting with Zejula. TNBC is a particularly challenging setting. There are many studies from numerous drug sponsors underway and TNBC, but there is no established reference standard for this disease.””

Morgan Stanley initiated coverage on shares of TherapeuticsMD (NYSEMKT:TXMD). They issued an equal weight rating and a $6.00 price target on the stock.

Versartis (NASDAQ:VSAR) had its buy rating reaffirmed by analysts at Piper Jaffray Companies. They currently have a $26.00 price target on the stock.

Wayfair (NYSE:W) had its buy rating reiterated by analysts at Piper Jaffray Companies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.